^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Truxima (rituximab-abbs)

    i
    Other names: CT-P10, TL011, TL 011
    Company:
    Celltrion, Indukern, Mundipharma, Nippon Kayaku, Teva
    Drug class:
    CD20 inhibitor
    Related drugs:
    1d
    Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    Rituxan (rituximab) • bortezomib • alisertib (MLN8237) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    3d
    Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, National Cancer Institute (NCI)
    New P1 trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    cisplatin • Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • vincristine • daunorubicin • Truxima (rituximab-abbs) • Columvi (glofitamab-gxbm) • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate)
    7d
    CD2 SCD: Siplizumab for Sickle Cell Disease Transplant (clinicaltrials.gov)
    P1/2, N=1, Terminated, Columbia University | N=18 --> 1 | Trial completion date: Jul 2029 --> Dec 2025 | Recruiting --> Terminated; Closed by the industry collaborator
    Enrollment change • Trial completion date • Trial termination
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Rituxan (rituximab) • cyclophosphamide • sirolimus • Truxima (rituximab-abbs)
    7d
    Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma (clinicaltrials.gov)
    P1/2, N=81, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=130 --> 81
    Enrollment closed • Enrollment change
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs)
    7d
    CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=18, Recruiting, Nathan Denlinger | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    clonoSEQ
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar) • golcadomide (CC-99282)
    7d
    Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (clinicaltrials.gov)
    P2, N=22, Terminated, University of Ulm | Phase classification: P=N/A --> P2
    Phase classification
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Keytruda (pembrolizumab) • Rituxan (rituximab) • Truxima (rituximab-abbs)
    14d
    Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL (clinicaltrials.gov)
    P1, N=15, Recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    Keytruda (pembrolizumab) • Rituxan (rituximab) • temozolomide • Truxima (rituximab-abbs)
    14d
    Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma (clinicaltrials.gov)
    P2, N=33, Recruiting, University of Washington | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ABL1 (ABL proto-oncogene 1) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive • CD20 negative
    |
    Rituxan (rituximab) • Iclusig (ponatinib) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Truxima (rituximab-abbs) • Neulasta (pegfilgrastim) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim)
    14d
    Pembrolizumab, Ibrutinib and Rituximab in PCNSL (clinicaltrials.gov)
    P1/2, N=37, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Imbruvica (ibrutinib) • Rituxan (rituximab) • Truxima (rituximab-abbs)
    17d
    DZ2024B0002: A Phase 3 Study of DZD8586 versus Investigators Choice in r/r CLL/SLL (2025-522669-32-00)
    P2/3, N=55, Recruiting, Dizal (Jiangsu) Pharmaceutical Co. Ltd.
    New P2/3 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Zydelig (idelalisib) • bendamustine • Truxima (rituximab-abbs) • birelentinib (DZD8586)
    17d
    D7402C00001: A trial to learn how safe AZD0486 is and how well it works in older or physically weak adults with large B-cell lymphoma when given after R-mini-CHOP (2025-522029-37-00)
    P2/3, N=30, Not yet recruiting, AstraZeneca AB
    New P2/3 trial
    |
    Rituxan (rituximab) • cyclophosphamide • vincristine • Truxima (rituximab-abbs) • Actemra IV (tocilizumab) • Neulasta (pegfilgrastim) • surovatamig (AZD0486)
    22d
    BEST-NMOSD: Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD (clinicaltrials.gov)
    P4, N=160, Not yet recruiting, Massachusetts General Hospital | Initiation date: Nov 2025 --> May 2026 | Trial primary completion date: Feb 2029 --> Jan 2030
    Trial initiation date • Trial primary completion date
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs) • Uplizna (inebilizumab-cdon)